Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The safety and efficacy of tagraxofusp for the treatment of BPDCN

Marco Herling • 12 Jun 2022
EHA 2022
Blastic Plasmacytoid Dendritic Cell Neoplasm Leukemia Rare Diseases Tagraxofusp

Marco Herling, MD, University of Leipzig, Leipzig, Germany shares some insights into a retrospective analysis investigating the safety and efficacy of tagraxofusp for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr Herling first highlights the importance of increasing awareness and improving treatment options for patients with BPDCN and also discusses the promising results observed with the use of tagraxofusp. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Marco Herling

1:00
Unmet needs in BPDCN: CNS involvement & the importance of intrathecal chemotherapy prophylaxis
Marco Herling • 25 Apr 2023
1:41
Improvements in the awareness and diagnosis of BPDCN
Marco Herling • 25 Apr 2023
1:15
Managing patients with transplant-ineligible BDPCN with tagraxofusp
Marco Herling • 25 Apr 2023
1:23
The challenge of relapse in transplant-eligible & transplant-ineligible patients with BDPCN
Marco Herling • 25 Apr 2023

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals